Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Winter-onset alopecia areata patients are more likely to regrow hair within a year compared to spring-onset patients.

In this study, baricitinib was well tolerated and led to clinical improvement in patients with treatment-resistant alopecia areata in a real-world clinical setting, suggesting it may be a potential treatment option.

In this pilot study, researchers found that betulin did not conclusively inhibit hair loss or promote regrowth in patients with hypothyroidism when compared to placebo.

This study documented three cases of acute thallium poisoning—one involving accidental overdose and two linked to intentional homicide—characterized by neurological and systemic symptoms, and in severe instances, death, underscoring thallium compounds' significant toxicity.

This case series described five patients with chronic alopecia areata who successfully maintained long-term disease control using a combination of topical immunotherapy and other treatments over 9–15 years, highlighting the approach's continued value alongside novel therapies.

Escin helps keep hair follicles in the growth phase longer.

In this study, 80% of pediatric patients with alopecia areata treated with calcipotriol/betamethasone ointment showed hair regrowth over 12 weeks, suggesting it may be an effective option, though 20% had no improvement or worsening symptoms.

In this study, researchers explored the effects of various medications on eye health, noting that systemic and local ophthalmic drugs can lead to both widespread and specific ocular side effects, with serious adverse events most associated with neurotropic, immunotropic, and antitumor medications.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

This source reports that in adults with non-scarring alopecia, polyphenolic interventions significantly improved hair density and total area hair count compared to controls, although considerable variability was present in results, highlighting the need for further research.

This systematic review and meta-analysis found that polyphenolic interventions significantly improved hair density and total area hair count in adults with non-scarring alopecia, but substantial heterogeneity was observed.

This case report describes the first instance of basal cell carcinoma developing at the site of repeated microneedling for androgenetic alopecia, highlighting the need for further safety studies.

This study developed consensus guidelines for the use of low-dose oral and topical minoxidil in male and female pattern hair loss, recommending specific doses, monitoring procedures, and timing of application around hair transplant surgeries.

This study developed expert consensus guidelines on using low-dose oral and topical minoxidil for pattern hair loss around hair transplant surgery, recommending specific doses, monitoring practices, and timing of use for both male and female patients.

This study developed consensus guidelines for using low-dose oral and topical minoxidil in patients undergoing hair transplant surgery for pattern hair loss, recommending dosing adjustments, monitoring protocols, and timing for post-surgery application.

This study found that early intervention and treatment with intralesional triamcinolone acetonide may stabilize hairline recession in patients with frontal fibrosing alopecia, although further research is needed for definitive treatment guidelines.

This study found that single high-dose irradiation in mice induced more severe acute skin injury and hair depigmentation, while fractional doses led to longer-term damage in the dermis and subcutis.

This study found that the CD44(+) ALDH(+) population of neonatal human keratinocytes exhibited enhanced stem cell properties, including significantly increased long-term epidermal regeneration and multipotency, compared to unfractionated cells.

This study observed that gold thread implantation increased hair regrowth in both human patients and mice, suggesting it could be an effective hair regrowth treatment, although further studies are needed to understand its mechanisms and safety.

This case report describes severe liver injury in a young patient after prolonged overuse of vitamin A, which resolved after cessation.

This study found that the less common CAG-rs4045402 and GGN-rs3138869 polymorphisms were more frequent in patients with post-finasteride syndrome and androgenetic alopecia, suggesting a genetic predisposition to AGA development.

This case report describes a Japanese bone marrow transplant recipient who developed a high-risk cutaneous squamous cell carcinoma on the scalp, potentially linked to long-term voriconazole use.

This paper outlines the research plan and current progress of a study analyzing mineral metabolism changes in astronauts by examining hair shafts after long-term space flight, with no new results yet.

This study examined the therapeutic response to folliculitis decalvans treatments among 60 patients and found that earlier disease onset was linked to more severe cases, while a combination of rifampicin, clindamycin, tetracyclines, and intralesional steroids was most effective in controlling symptoms.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

This article reviews the symptoms, diagnosis, and management of polycystic ovary syndrome, emphasizing lifestyle changes and medical interventions, but presents no new findings.

This study found that nearly 40% of Hodgkin’s Lymphoma patients who received Brentuximab Vedotin with AVD chemotherapy experienced persistent alopecia more than two years after treatment, leading to significant psychosocial consequences such as reduced self-confidence and emotional distress.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This article discusses the concept of "donor dominance" in androgenetic alopecia, where grafted hair continues to grow in bald areas, but reports no new clinical findings.